US Pharma MarketingApogee lands Blackstone $800M royalty deal to move Dupixent rival toward Phase 3
Apogee Therapeutics secures up to $800 million royalty deal with Blackstone Life Sciences to fund Phase 3 trials of eczema drug zumilokibart. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push…
The biggest question Apogee Therapeutics CEO Michael Henderson gets from investors?
"These are big markets, this takes a lot of capital — are you just going to dilute us every time you have data?" Henderson said ...
Source: Endpoints News